Tandem Diabetes Beats Q1, But Profitability Remains Elusive

Tandem Diabetes Care exceeded revenue expectations in Q1 2026, reporting $247M, a 5.5% increase from last year and surpassing Wall Streets $239M forecast. Despite GAAP EPS loss of $0.30, better than expected $0.44, full-year revenue guidance of $543M fell short of analyst hopes. The companys automated insulin delivery systems, integrating continuous glucose monitoring, have driven 13.6% CAGR over five years. Investors reacted positively, with stock jumping 10.9% to $20.50, valuing the company at $1.24B. While top-line numbers were strong, profitability remains a challenge with adjusted operating margin at -7.1%. Adjusted EBITDA doubled to $2.73M, and operating margins improved significantly. Analysts predict 7.5% revenue growth and narrowed EPS losses in the next year. Despite short-term victories, the path to profits is still long, with market reception of their tech crucial for future success. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0a3c10f6d914bffb